Last reviewed · How we verify
NCT05442749: PARPi-PANC
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
Phase 2 trial testing Niraparib in Metastatic Pancreatic Cancer in 2 participants. Terminated before completion.
30 August 2024
Quick facts
| Lead sponsor | Centre Leon Berard |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 28 October 2022 |
| Primary completion | 30 August 2024 |
| Estimated completion | 30 August 2024 |
| Sites | 4 locations across France |
Drugs / interventions tested
- Niraparib (niraparib) — full drug profile →
Conditions studied
- Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →
Sponsor
Centre Leon Berard — full company profile →
Who can join
18 and older, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a single arm open-label, phase II aiming to assess the clinical activity of niraparib in chemotherapy-naïve biomarker-selected pancreatic cancer patients.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent advances in targeted therapy for pancreatic adenocarcinoma.
Fang YT, Yang WW, Niu YR, Sun YK. · · 2023 · cited 34× · PMID 37123059 · DOI 10.4251/wjgo.v15.i4.571 -
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS, Pellat A, Brezault C, Dhooge M, et al · · 2022 · cited 22× · PMID 36399952 · DOI 10.1016/j.esmoop.2022.100638 -
Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair-associated gene alterations in solid tumors from a large Asian cohort.
Ren L, Yao R, Hou T, Liu C, et al · · 2025 · cited 5× · PMID 40420266 · DOI 10.1186/s12885-025-14267-w -
Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma.
Di Marco F, Cufaro MC, Damiani V, Dufrusine B, et al · · 2025 · cited 1× · PMID 39956821 · DOI 10.1038/s41389-025-00547-4
Verify or expand the search:
- PubMed search for NCT05442749
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Niraparib
Trials testing the same drug.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06682780 — A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
- NCT06887933 — A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ov · Phase 4 · not yet recruiting
- NCT05672095 — Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · Phase 1, PHASE2 · withdrawn
Other recruiting trials for Metastatic Pancreatic Cancer
Currently open trials in the same condition.
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
- NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
- NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
- NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting
Other Centre Leon Berard trials
Trials by the same sponsor.
- NCT07499921 — Clinical and BIOgical Analyses of RECtal Tumors · NA · not yet recruiting
- NCT07515274 — Evaluation of the Effects of Equicoaching on Social Reintegration Among Young Adults Who Have Been Treated for Cancer · NA · not yet recruiting
- NCT07243483 — Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute My · NA · recruiting
- NCT07334990 — Impact of a Hypnotic Recording on Artifacts in 4D CT in the Context of Stereotactic Body Radiation Therapy for Lung Canc · NA · not yet recruiting
- NCT07414719 — Impact of an HPV Primary Prevention Intervention on HPV Vaccination Rates Among Adolescents in the AuRA Region. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05442749 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Leon Berard
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05442749.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing